創益生技股份有限公司

Banner Up

International Partners

 
AngioLab is a biotechnology company that is engaged in the discovery, development, and commercialization of anti-angiogenic candidates for the inhibition of abnormal new blood vessel growth. AngioLab was founded in 1999. It has many prior experiences and core technologies in the research of angiogenesis. It has over 60 related patents (including domestic and international patents and pending patents). AngioLab is currently seeking suitable partners and investors for the promotions of new anti-angiogenic drugs to international markets. 

The AngioLab products aside from drugs (abdominal obesity, age-related macular degeneration, and periodontal lesions) also include health supplement foods (Korea approved health care product that reduces visceral fat and metabolic syndromes) and cosmetics (reducing UV exposure wrinkles) that resulted from the anti-angiogenesis technologies. Of these products, the health supplement food has already being sold in Korea, United States, and France; and the cosmetics are being sold in Korea.

CYBiotech has obtained the exclusive license for Ob-X from AngioLab in Taiwan in Dec, 2014. CYBiotech will continue the development and sales of Ob-X in Taiwan.